Gossamer Bio, Inc. — SEC Form D Filing
Gossamer Bio, Inc. filed an SEC Form D on September 4, 2026, reporting $25.00M raised in Biotechnology.
Form D filing details
- Filing
- SEC Form D
- Filing date
- September 4, 2026
- Amount reported
- $25.00M
- Round stage
- Series B+
- Industry
- Biotechnology
- Website
- https://www.gossamerbio.com/
What the company does
Exemption: Rule 506(b). Incorporated: DELAWARE
Problem
People suffer from rare diseases such as pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).
Solution
Gossamer Bio is developing seralutinib, an investigational inhaled PDGFRα/β, CSF1R, and c‑KIT inhibitor delivered via a dry powder inhaler, for the treatment of PAH and PH-ILD.
Why now
Advances in understanding specific disease pathways and the development of targeted therapies for rare diseases allow for the creation of new, potentially life-changing treatments.
Verdict
Investors backed this because the narrative offered a clear de-risking pathway in a high-value rare disease segment, positioning Gossamer Bio for a potential acquisition or accelerated approval. This cleared because of the established regulatory and commercial precedent for rare disease assets, not because of novel platform technology. The implicit bet was on clinical trial success and market exclusivity, which simultaneously limited upside by tying valuation tightly to a single asset's performance rather than a broader pipeline.
Source: SEC EDGAR Form D filing